2026-10-04
Advanced Biomed clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 30,808 +1.00%
S&P 7,723 +0.73%
GOLD $4,168 +0.14%
BTC $86,421 +1.96%
VIX 15.31 −6.59%
live tape · as of 03:09 UTC
The Screen · Healthcare · Diagnostics & Research
Advanced Biomed Inc
ADVB · NASDAQ · USD · Market cap $8M · 31 employees
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan.
Not yet scored6.47 USD
Screen close, 2025-06-30 · not a live quote
Last reviewed 462 days ago
Screened 2025-06-30 · the tape above runs as of 03:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 6.47 against the desk's fair-value range, over the last year.
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price6.47 USD
Ethical score70.0/100
Our investment reviews on this name
2026-09-19Read Markdown5.03+28.6% to today
2026-08-20Read Markup5.03+28.6% to today ✓
2026-07-02Read Distribution4.50+43.8% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markdown label.
Advanced Biomed Inc holds its Markdown at $6.47. Consolidating, no directional conviction, held for 20 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 20 days |
| Price at the screen | $6.47 |
| Valuation | 1.62 trailing · N/A forward price to earnings |
| Values screen | Not scored · score 70.0 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Advanced Biomed clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
We do not yet have the financial statements needed to run the debt, cash, receivables and income screens for Advanced Biomed, so it is not scored yet.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
The Business, in Plain Words| Trailing P/E | 1.6xvery cheap relative to earnings |
| EPS, trailing | 4.00 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | 71.3%an exceptional return on shareholder capital |
| FCF yield | -102.14% |
| Debt to equity | 0.08minimal debt: a conservative balance sheet |
| Current ratio | 7.38comfortably covers its short-term bills |
| Short interest, float | 0.02% |
| 52-week range | 3.61 - 15.20 |
| Moat | NONE |
| Market cap | $8M |
| Employees | 31 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeADVB trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-02
Markdown $6.47
+28.6% Entry 8
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 28.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-09-19
Markdown · changed $5.03
+0.0% Entry 7
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-08-20
Markup · changed $5.03
+0.0% Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-07-20
Distribution $5.03
+11.8% Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 11.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-07-18
Distribution $4.50
+0.0% Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-07-16
Distribution $4.50
+0.0% Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-07-03
Distribution $4.50
+0.0% Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02
Distribution $4.50
Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
MBAICheck-Cap Ltd.
XWELXWELL Inc
NDRAENDRA Life Sciences Inc
BIAFBioAffinity Technologies Inc
ISPCiSpecimen Inc
MDXHMDxHealth SA
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $5.01 | -22.2% | · | $778 | -22.2% |
| 2 months | $6.60 | -40.9% | · | $591 | -40.9% |
| 3 months | $5.36 | -27.2% | · | $728 | -27.2% |
| 6 months | $7.32 | -46.7% | · | $533 | -46.7% |
| 1 year | $18.62 | -79.1% | · | $210 | -79.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ADVB does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.